Summary of business development

Carl Zeiss Meditec AG ended fiscal year 2024/25 with a slight increase in revenue. This means that the past fiscal year was once again on a growth trajectory. The revenue forecast for Carl Zeiss Meditec AG was achieved, while the EBIT forecast was not met.

Revenue increased by 4.1% year-on-year and was therefore slightly below the development of the Carl Zeiss Meditec Group as a whole. Exchange rate fluctuations had no material effect overall on the development of revenue. EBIT (revenue plus changes in inventories, other own work capitalized, other operating income less cost of materials and personnel expenses, depreciation, amortization and write-downs and other operating expenses) decreased by -€20.4m compared to the prior year (€202.8m) to €182.4m. The EBIT margin thus decreased by 1.9 percentage points, from 14.3% in the prior year to 12.4%.